TerSera Therapeutics

ETODOLAC

etodolac

Post-LOE

ORAL · TABLET

CLINICAL PHARMACOLOGY Pharmacodynamics Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of etodolac, like that of other NSAIDs, is not completely understood, but may be related to the prostaglandin synthetase inhibition. Etodolac is a racemic mixture of [-]R- and [+]S-etodolac. As with other NSAIDs, it has been demonstrated in animals that the [+]S-form is biologically active. Both enantiomers are stable and there is no [-]R to [+]S conversion in vivo . Pharmacokinetics Absorption The systemic bioavailability of etodolac from etodolac capsules and tablets is 100% as compared to solution and at least 80% as determined from mass balance studies. Etodolac is well absorbed and had a relative bioavailability of 100% when 200 mg capsules were compared with a solution of etodolac. Based on mass balance studies, the systemic availability of etodolac from either the tablet or capsule formulation is at least 80%. Etodolac does not undergo significant first-pass metabolism following oral administration. Mean (± 1 SD) peak plasma concentrations (C max ) range from approximately 14 ± 4 to 37 ± 9 μg/mL after 200 to 600 mg single doses and are reached in 80 ± 30 minutes (see for summary of pharmacokinetic parameters). The dose-proportionality based on the area under the plasma concentration-time curve (AUC) is linear following doses up to 600 mg every 12 hours. Peak concentrations are dose proportional for both total and free etodolac following doses up to 400 mg every 12 hours, but following a 600 mg dose, the peak is about 20% higher than predicted on the basis of lower doses. The extent of absorption of etodolac is not affected when etodolac tablets or capsules are administered after a meal. Food intake, however, reduces the peak concentration reached by approximately one-half and increases the time to peak concentration by 1.4 to 3.8 hours. Table 1. Mean (CV%) % Coefficient of variation Pharmacokinetic Parameters of etodolac in Normal Healthy Adults and Various Special Populations PK Parameters Normal Healthy Adults (18-65) Age Range (years) Healthy Males (18-65) Healthy Females (27-65) Elderly (>65) (70-84) Hemodialysis (24-65) (n=9) Renal Impairment (46-73) Hepatic Impairment (34-60) (n=179) (n=176) (n=3) Dialysis On Dialysis Off (n=10) (n=9) NA = not available T max , h 1.4 (61%) 1.4 (60%) 1.7 (60%) 1.2 (43%) 1.7 (88%) 0.9 (67%) 2.1 (46%) 1.1 (15%) Oral Clearance, mL/h/kg (CL/F) 49.1 (33%) 49.4 (33%) 35.7 (28%) 45.7 (27%) NA NA 58.3 (19%) 42.0 (43%) Apparent Volume of Distribution, mL/kg (Vd/F) 393 (29%) 394 (29%) 300 (8%) 414 (38%) NA NA NA NA Terminal Half-Life, h 6.4 (22%) 6.4 (22%) 7.9 (35%) 6.5 (24%) 5.1 (22%) 7.5 (34%) NA 5.7 (24%) Distribution The mean apparent volume of distribution (Vd/F) of etodolac is approximately 390 mL/kg. Etodolac is more than 99% bound to plasma proteins, primarily to albumin. The free fraction is less

Pipeline & Clinical Trials

Xermelo

Carcinoid Syndrome

N/A

Clinical Trials (1)

NCT03223428Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

N/A

Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score

Prostate Cancer

N/A

Clinical Trials (1)

NCT05820633Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.

N/A

SBRT combined with ADT

Prostate Cancer (Adenocarcinoma)

N/A

Clinical Trials (1)

NCT07460726PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer

N/A

Margetuximab

HER2-positive Breast Cancer

N/A

Clinical Trials (1)

NCT03133988Margetuximab Expanded Access Program

N/A

Standard Fractionation Post-Operative Salvage Radiotherapy

Reccurent/Metastatic Solid Tumor Disease

N/A

Clinical Trials (1)

NCT07483658Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

N/A

Ziconotide

Chemotherapy Induced Peripheral Neuropathy (CIPN)

N/A

Clinical Trials (1)

NCT07499882Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

N/A

ZOLADEX

Advanced Breast Cancer

PHASE_1

Clinical Trials (1)

NCT07310420A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 1

Telotristat

Neuroendocrine Tumors

PHASE_2

Clinical Trials (1)

NCT04543955Telotristat With Lutathera in Neuroendocrine Tumors

Phase 2

Cetirizine HCl 10 mg/mL

Oncology Patients Receiving Chemotherapy

PHASE_2

Clinical Trials (1)

NCT04189588Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

Phase 2

telotristat ethyl

Biliary Tract Cancer (BTC)

PHASE_2

Clinical Trials (1)

NCT03790111A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Phase 2

Radiotherapy

Prostate Metastases

PHASE_2

Clinical Trials (1)

NCT05656794Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

Phase 2

About TerSera Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (7)

Key Products by Revenue

Other Products (3)

Pipeline & Clinical Trials

Open Jobs (0)

Hiring Trend

Research Publications(8)